Source: International Congress 2019 – Biology and prognosis of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Martins Baptista (Covilhã, Portugal), N. Martins (Porto, Portugal), J. Barata (Covilhã, Portugal), R. Silva (Covilhã, Portugal), S. Martins (Covilhã, Portugal), A. Craveiro (Covilhã, Portugal), M. Valente (Covilhã, Portugal), E. Magalhães (Covilhã, Portugal), I. Vicente (Covilhã, Portugal), M. Valente (Covilhã, Portugal). Molecular biology of advanced NSCLC and survival: seeking the best therapy. 3054

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 178-185 Year: 2015 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the (pneumo) oncologist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Modern profiling of advanced lung cancer at the primary diagnosis and during therapy Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Eminence or evidence based ? – personalised diagnostic-therapeutic sequences in a molecular altered advanced NSCLC patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Challenges in molecular testing in lung cancer patients with advanced disease Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002